News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
234,256 Results
Type
Article (18932)
Company Profile (161)
Press Release (215160)
Multimedia
Podcasts (49)
Webinars (6)
Section
Business (62000)
Career Advice (198)
Deals (9060)
Drug Delivery (63)
Drug Development (34116)
Employer Resources (34)
FDA (6867)
Job Trends (6278)
News (112710)
Policy (11437)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1591)
Academic (1)
Accelerated approval (17)
Adcomms (13)
Allergies (72)
Alliances (17862)
ALS (77)
Alzheimer's disease (731)
Antibody-drug conjugate (ADC) (138)
Approvals (7159)
Artificial intelligence (262)
Autoimmune disease (84)
Automation (18)
Bankruptcy (55)
Best Places to Work (5989)
BIOSECURE Act (7)
Biosimilars (134)
Biotechnology (112)
Bladder cancer (92)
Brain cancer (24)
Breast cancer (321)
Cancer (2432)
Cardiovascular disease (254)
Career advice (184)
Career pathing (7)
CAR-T (151)
CDC (16)
Celiac Disease (1)
Cell therapy (411)
Cervical cancer (13)
Clinical research (30345)
Collaboration (950)
Company closure (1)
Compensation (396)
Complete response letters (19)
COVID-19 (1143)
CRISPR (69)
C-suite (442)
Cystic fibrosis (94)
Data (3591)
Decentralized trials (1)
Denatured (22)
Depression (67)
Diabetes (277)
Diagnostics (2351)
Digital health (21)
Diversity (8)
Diversity, equity & inclusion (13)
Drug discovery (143)
Drug pricing (119)
Drug shortages (19)
Duchenne muscular dystrophy (133)
Earnings (20316)
Editorial (23)
Employer branding (2)
Employer resources (34)
Events (35476)
Executive appointments (482)
FDA (8574)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (12)
Funding (649)
Gene editing (141)
Generative AI (27)
Gene therapy (363)
GLP-1 (548)
Government (1713)
Grass and pollen (2)
Guidances (170)
Healthcare (7665)
HIV (40)
Huntington's disease (24)
IgA nephropathy (53)
Immunology and inflammation (99)
Immuno-oncology (30)
Indications (65)
Infectious disease (1271)
Inflammatory bowel disease (124)
Inflation Reduction Act (7)
Influenza (54)
Intellectual property (80)
Interviews (14)
IPO (4371)
IRA (27)
Job creations (725)
Job search strategy (167)
JPM (32)
Kidney cancer (10)
Labor market (18)
Layoffs (145)
Leadership (8)
Legal (1807)
Liver cancer (41)
Longevity (7)
Lung cancer (341)
Lymphoma (237)
Machine learning (21)
Management (11)
Manufacturing (392)
MASH (93)
Medical device (2668)
Medtech (2682)
Mergers & acquisitions (5117)
Metabolic disorders (700)
Multiple sclerosis (74)
NASH (12)
Neurodegenerative disease (145)
Neuropsychiatric disorders (38)
Neuroscience (1341)
NextGen: Class of 2026 (2141)
Non-profit (1713)
Now hiring (15)
Obesity (333)
Opinion (98)
Ovarian cancer (83)
Pain (114)
Pancreatic cancer (93)
Parkinson's disease (131)
Partnered (14)
Patents (153)
Patient recruitment (231)
Peanut (24)
People (23215)
Pharmaceutical (33)
Pharmacy benefit managers (15)
Phase 1 (8461)
Phase 2 (12272)
Phase 3 (11866)
Pipeline (2600)
Policy (150)
Postmarket research (1436)
Preclinical (3338)
Press Release (15)
Prostate cancer (122)
Psychedelics (15)
Radiopharmaceuticals (159)
Rare diseases (501)
Real estate (1568)
Recruiting (11)
Regulatory (10305)
Reports (13)
Research institute (1393)
Resumes & cover letters (17)
Rett syndrome (24)
RNA editing (11)
RSV (32)
Schizophrenia (78)
Series A (127)
Series B (98)
Sickle cell disease (75)
Special edition (8)
Spinal muscular atrophy (91)
Sponsored (17)
Startups (1381)
Stomach cancer (7)
Supply chain (49)
Tariffs (52)
The Weekly (26)
Vaccines (398)
Venture capital (42)
Weight loss (218)
Women's health (41)
Worklife (1)
Date
Last 7 days (275)
Last 30 days (1010)
Last 365 days (13996)
2026 (1379)
2025 (14144)
2024 (15466)
2023 (16760)
2022 (20918)
2021 (21715)
2020 (19863)
2019 (17100)
2018 (12832)
2017 (12037)
2016 (11198)
2015 (12068)
2014 (8452)
2013 (6942)
2012 (7035)
2011 (7000)
2010 (5671)
Location
Africa (245)
Alabama (30)
Alaska (1)
Arizona (60)
Arkansas (3)
Asia (15807)
Australia (2168)
California (4956)
Canada (1140)
China (576)
Colorado (163)
Connecticut (247)
Delaware (228)
Europe (35504)
Florida (682)
Georgia (134)
Hawaii (1)
Idaho (15)
Illinois (395)
India (35)
Indiana (326)
Iowa (6)
Japan (313)
Kansas (54)
Kentucky (9)
Louisiana (11)
Maine (28)
Maryland (499)
Massachusetts (4112)
Michigan (48)
Minnesota (128)
Mississippi (1)
Missouri (65)
Montana (9)
Nebraska (4)
Nevada (30)
New Hampshire (14)
New Jersey (1721)
New Mexico (11)
New York (1395)
North Carolina (643)
North Dakota (6)
Northern California (2603)
Ohio (123)
Oklahoma (5)
Oregon (22)
Pennsylvania (971)
Puerto Rico (3)
Rhode Island (17)
South America (301)
South Carolina (8)
Southern California (1799)
Tennessee (46)
Texas (589)
United States (17916)
Utah (153)
Vermont (1)
Virginia (130)
Washington D.C. (44)
Washington State (427)
Wisconsin (49)
234,256 Results for "editas medicine".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
November 10, 2025
·
9 min read
Press Releases
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
November 4, 2025
·
1 min read
Press Releases
Editas Medicine to Participate in Upcoming September 2025 Investor Conferences
August 28, 2025
·
1 min read
Press Releases
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
September 3, 2025
·
7 min read
Press Releases
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
August 29, 2025
·
1 min read
Press Releases
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
August 13, 2025
·
9 min read
Press Releases
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
October 10, 2025
·
2 min read
Press Releases
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
October 7, 2025
·
2 min read
Press Releases
Editas Medicine Announces First Quarter 2025 Results and Business Updates
May 12, 2025
·
11 min read
Press Releases
Editas Medicine Announces Chief Financial Officer Transition
March 21, 2025
·
3 min read
1 of 23,426
Next
